Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Webinar – Understanding the Chinese drug market

On Thursday 24th September 2020, at 10:00 CET (Central European Time), ELC, in conjunction with our local expert from China, Dr. Zhou, will be hosting a webinar providing an overview of the Chinese drug market and detailing access strategies.

Dr. Zhou is responsible for global alliances and evaluation of innovative drugs, generics & APIs for development and licensing.
He had a successful track record for numerous licensing-in/out projects as well as partnerships between Chinese and global pharmaceutical companies including Innovent Biologics and Eli Lilly.
He has extensive experience in optimizing successful product strategy and expansion into new markets.

We are going to take you through the following topics:

  1. Overview of the China drug market
  2. Drug licensing-out: Preparing for international alliance with China
  3. Guidance on China drug market entry
  4. China drug market reforms and business strategy

To participate, please fill in the form below.
You will then receive an invitation to this webinar.
Please note that the number of participants is limited.

The entrance is free of charge.